Learn Mode

BMRN - BioMarin Pharmaceutical Inc

35

$54.14

-$1.41 (-2.538%)

At close: 3/27/26, 8:00 PM

3.85/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

BMRN

Valuation Score

View as %

Stock Unlock

1D

1W

1M

YTD

1Y

3Y

5Y

Max

Stock Profile

Market Cap

$10.41B

Industry

Biotechnology

EPS (TTM)

$1.81

P/E (TTM)

29.84

Div & Yield

--

FCF Payout Ratio

--

P/S (TTM)

3.23

P/B

1.71

Diluted Shares

192.23M

Ex-Dividend

--

Next Earnings

04-29

Forward P/E

12.23

Payout Ratio

--

P/FCF (TTM)

14.52

FCF Yield

6.89%

Earnings Yield

3.35%

52 Week Range

Score Card

Explore Scores Tab

3.85

Good

BioMarin Pharmaceutical Inc has grown revenue at 12.87% over the past year, which is strong growth. Also, it has more cash than liabilities meaning it could use its current cash position to be completely debt-free, if it wanted to.

Valuation Model

Key Score

1.00

Very Bad

Management

2.00

Bad

Growth

4.00

Good

Profitability

5.00

Very Good

Fin. Health

5.00

Very Good

Dividends

--

--

Analyst

3.00

Average

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

1 new filing was in the last 7 days

Filter Form Types

Form SCHEDULE 13G/A

Unknown Form Type

Filed on 2026-03-26 16:09:48

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-19 16:53:12

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-19 16:50:54

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-19 16:48:04

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-19 16:34:31

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-18 13:42:15

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-18 13:39:42

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-17 20:50:38

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-17 20:48:08

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-17 20:45:54

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-17 20:43:06

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-03-16 08:30:06

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-02-21

High:

$126.00

132.7%

Avg:

$92.49

70.8%

Low:

$60.60

11.9%

(% change is relative to the current stock price: $54.14)

Analyst Recommendations

Go to Analyst Tab

4.06

Good

28%

Strong Buy (9)

50%

Buy (16)

22%

Hold (7)

0%

Sell (0)

0%

Strong Sell (0)

About

Website
https://www.biomarin.com/
Address
770 Lindaro Street, San Rafael California CALIFORNIA, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=1048477

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. The company is headquartered in San Rafael California, California and currently employs 3,221 full-time employees. The firm has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.

IPO Date

1999-07-23

Industry

Biotechnology

Total Employees

3,221

Exchange

Nasdaq Nms - Global Market

Reporting Currency

USD

GICS

Biotechnology

GICS Sub

Biotechnology

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences